This year, six biosimilars for the top-selling medicine, Humira, will enter the market, with the first launching on January 31, 2023. Increased competition from biosimilars can drive down costs. But experts argue that insurer...
Can a divided Congress work together to help patients? Health policy experts Jon Deuser and Mike Gaffin tackle that question. They explain what health care issues Congress might address, including the lack of transparency aro...
A new Alzheimer’s treatment received FDA approval under the accelerated approval program. Former FDA Associate Commissioner Peter Pitts explains how the accelerated approval pathway leads to incremental innovation, or buildin...
Last year President Biden signed the Inflation Reduction Act into law, which included several changes to Medicare. Terry and Dr. Bob discuss the three changes that start this year, including the $35 monthly cap on insulin, an...